| Zheng, Tongsen |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Withdrawn | 1 | 73 | RoW | TQB3015 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 05/24 | 05/24 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
NCT05770310: A Phase I Study Of JS015 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 114 | RoW | JS015 | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Advanced Solid Cancer | 06/24 | 07/25 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
